NovoCodex Biopharmaceuticals
Shaoxing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing precision ADCs using synthetic amino acid site-specific conjugation technology for cancer treatment.
Oncology
Technology Platform
Site-specific antibody-drug conjugation platform using synthetic non-natural amino acids for precise control over drug-to-antibody ratios and conjugation sites.
Opportunities
Growing global ADC market valued at over $10 billion, China's supportive biopharma policy environment, and potential for platform technology licensing or co-development partnerships.
Risk Factors
Intense competition in ADC space from established players like Seagen/Astellas and numerous Chinese biotechs, clinical development risks for novel conjugation technologies, and dependency on parent company funding.
Competitive Landscape
Competes with ADC leaders like Seagen, Daiichi Sankyo, and ImmunoGen, plus Chinese peers such as RemeGen and Hengrui Medicine, differentiating through proprietary site-specific conjugation using synthetic amino acids.